Special Issue "Advanced Systems in Targeted Alpha Particle Therapy"
Deadline for manuscript submissions: closed (10 August 2022) | Viewed by 6410
It has now been almost 30 years of research and development efforts in the rediscovered field of targeted alpha particle therapy. Many novel isotope production methods, new targeting molecules, and nanocarriers together with preclinical or clinical trials and first-in-patient studies have moved this field forward by leaps and bounds. This successful progress has resulted in the global acceptance of alpha emitters, like the 223RaCl2 or 225Ac-PSMA-617, powerful tools in clinical praxis, and experimental cancer treatment. Targeted alpha particle therapy (TAT) has become a regular therapeutic modality in the treatment of cancer.
This Special Issue focuses on the latest innovations and studies in the field of TAT, including the preparation and testing of novel carriers, targeting systems, and medical devices, particularly those exploiting or suppressing the nuclear recoil effect in so-called in vivo radionuclide generators. In vitro stability and in vivo biodistribution studies, dosimetric studies, therapeutic efficacy determinations in various models, clinical trials, and other related research are welcome as full papers, communications, or reviews.
Prof. Ján Kozempel
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Materials is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- Alpha particle
- Chain decay
- In vivo generators
- Nuclear recoil effect
- targeted alpha therapy